Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215321 | 0.98 | HRH3 (0.61) | HRH3MMP1MMP2MMP9MMP13 | |
| SCHEMBL1432514 | 0.86 | HRH3 (0.62) | HRH3MMP1MMP2MMP9MMP13 | |
| Hydrochloric Acid SCHEMBL12079608 | 0.85 | HRH3 (0.61) | HRH3MMP1MMP2MMP9MMP13 | |
| SCHEMBL15650519 | 0.84 | HRH3 (0.60) | HRH3DHFREGFRERBB2MEN1 | |
| SCHEMBL8280912 | 0.84 | HRH3 (0.63) | HRH3DHFREGFRMEN1KMT2A | |
| SCHEMBL10425978 | 0.79 | HRH3 (0.57) | HRH3MEN1KMT2AKDM4E | |
| SCHEMBL3265007 | 0.78 | ACKR3 (0.49) | HRH3GSK3B | |
| SCHEMBL23120482 | 0.76 | DDB1 (0.47) | HRH3MMP1MMP2MMP9MMP13 | |
| SCHEMBL16706688 | 0.75 | LMNA (0.54) | MEN1KMT2AKDM4E | |
| SCHEMBL3386166 | 0.75 | HRH3 (1.00) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
| US-10118933-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2018-11-06 | — | — | US | disclosed |
| EP-3369732-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2018-09-05 | — | — | EP | disclosed |
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2017-09-14 | — | — | US | disclosed |
| EP-3056485-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2016-08-17 | — | — | EP | disclosed |
| CN-102596910-B | Androgen receptor modulating compounds | ORION CORP. (FI) | 2015-11-25 | — | — | CN | disclosed |
| CN-105061313-A | Androgen receptor modulating compounds | ORION CORP | 2015-11-18 | — | — | CN | disclosed |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION | 2015-07-23 | — | — | US | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260206-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
| US-10118933-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HRH3 3401/4885MMP1 4516/4885MMP2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.